関連する実験動画

Updated: May 5, 2026

A Murine Model of Muscle Training by Neuromuscular Electrical Stimulation

A Murine Model of Muscle Training by Neuromuscular Electrical Stimulation

Published on: May 9, 2012

重度の心不全の入院患者における神経筋肉の電気刺激後のパフォーマンスの改善

Theresa Maria Betz¹, Hannes Kinitz¹, Isabel Kristen¹

¹Department of Sports Medicine, Medical Clinic, University Hospital Heidelberg, Im Neuenheimer Feld 410, Heidelberg 69120, Germany.

ESC heart failure

|February 19, 2026

まとめ

神経筋電動刺激 (NMES) は,入院した重症心不全患者の機能的パフォーマンスを安全に改善しました. このセラピーは,理学療法に加えると,StimFIT5スコアを,特に体調不良の個体において,著しく向上させました.

科学分野:

心臓病学心臓病学
リハビリテーション医学リハビリテーション医学
バイオメディカルエンジニアリング

背景:

深刻な心不全の患者はしばしばサルコペニアを経験し,運動能力の低下につながります.
病院に入院すると,これらの患者の筋肉喪失と機能低下が悪化する可能性があります.
既存の治療法は,重度の心不全における機能的欠陥を完全に対処できない可能性があります.

研究の目的:

入院中の重症心不全患者の神経筋肉電気刺激 (NMES) の安全性と有効性を評価する.
物理療法の補助として,NMESが機能的パフォーマンスに与える影響を評価する.
心臓の電子機器を持つ患者のNMES効果を調査する.

主な方法:

30人の重度の心不全患者は,対照群 (理学療法のみ) または刺激群 (理学療法+2週間のNMES) にランダムに分けられました.
機能的パフォーマンスは,5つのテストを使用して測定され,ベースラインと2週間でStimFIT5-Scoreに集約されました.
心臓器具を装着した患者の電気磁気干渉を含む安全性が監視されました. 抑うつ症状 (PHQ9-スコア) も評価されました.

主要な成果:

NMESは安全で,心臓器具の患者では有害事象や電磁気干渉はありませんでした.
NMESグループは,対照グループと比較して,StimFIT5スコアで有意に大きな改善を示しました.
改善は最も体調が悪い患者で顕著であり,6分間の歩行テストと座り立てテストで有意な改善が見られた.

結論:

NMESは,心臓の電子機器を持つ患者を含む,入院した重症心不全患者のための安全な治療法です.
理学療法にNMESを追加すると,StimFIT5-Scoreで測定されるように,機能的パフォーマンスを大幅に改善します.
NMESの利点は,性別に関係なく,基礎値より低い機能能力を有する患者において最も顕著である.

キーワード:

電子心臓器具とは機能的パフォーマンスの性能心不全は,心不全によるものです.神経筋肉の電気刺激による電気刺激サルコペニア (Sarcopenia) とは

さらに関連する動画

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity

Published on: January 10, 2013

Paradigms of Lower Extremity Electrical Stimulation Training After Spinal Cord Injury

Paradigms of Lower Extremity Electrical Stimulation Training After Spinal Cord Injury

Published on: February 1, 2018

関連する概念動画

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Heart Failure VII: Nursing Interventions

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...